ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries.
Baird analyst Eric Coldwell lowered the firm’s price target on Icon (ICLR) to $203 from $221 and keeps a Neutral rating on the shares. The firm ...
ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 85% Above Its Share Price
Our fair value estimate is 34% higher than ICON's analyst price target of US$257 Does the February share price for ICON Public Limited Company (NASDAQ:ICLR) reflect what it's really worth?
ICON has seen a decline in its non-current bank and loan debts of 36.88% since 2021. Click here to find out why ICLR stock is a Buy.
Equities researchers at Leerink Partnrs reduced their FY2025 earnings estimates for ICON Public in a research report issued ...
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback